Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 745.22M P/E 1,188.00 EPS this Y -370.00% Ern Qtrly Grth -
Income -11.45M Forward P/E 79.20 EPS next Y 77.80% 50D Avg Chg -18.00%
Sales 140.94M PEG -1.68 EPS past 5Y - 200D Avg Chg -25.00%
Dividend N/A Price/Book 3.93 EPS next 5Y 15.00% 52W High Chg -44.00%
Recommedations 2.00 Quick Ratio 0.72 Shares Outstanding 63.24M 52W Low Chg 5.00%
Insider Own 1.05% ROA -1.36% Shares Float 58.37M Beta 1.65
Inst Own 91.93% ROE -6.28% Shares Shorted/Prior 10.84M/5.65M Price 11.88
Gross Margin 12.52% Profit Margin -8.12% Avg. Volume 579,688 Target Price 12.25
Oper. Margin -44.19% Earnings Date Mar 28 Volume 520,273 Change -0.25%
About Avid Bioservices, Inc.

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

Avid Bioservices, Inc. News
03/20/24 Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q
03/10/24 Avid Bioservices Inc (CDMO) Releases Preliminary Q3 Financial Results
03/06/24 Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
03/06/24 Avid Bioservices Announces Proposed Private Placement of Convertible Notes
03/06/24 Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024
01/30/24 Avid Bioservices (CDMO) Declined in 2023
01/12/24 Insider Stock Buying Reaches US$527.5k On Avid Bioservices
12/19/23 Director Richard Hancock's Strategic 23,000 Share Purchase in Avid Bioservices Inc
12/08/23 Avid Bioservices, Inc. (NASDAQ:CDMO) Q2 2024 Earnings Call Transcript
12/07/23 Avid Bioservices Inc (CDMO) Adjusts Fiscal 2024 Revenue Guidance Amidst Second Quarter Challenges
12/07/23 Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates
12/07/23 Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023
12/01/23 Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
11/30/23 Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023
09:35 AM Down -22.27% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround
11/15/23 Avid Bioservices (CDMO) Moves 9.0% Higher: Will This Strength Last?
11/14/23 Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study
11/11/23 Avid Bioservices (NASDAQ:CDMO investor one-year losses grow to 67% as the stock sheds US$88m this past week
11/09/23 Jazz (JAZZ) Lags Q3 Earnings, Beats Sales, Raises '23 View
11/08/23 Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs
CDMO Chatroom

User Image ForUS2Retire Posted - 1 week ago

Here's A Link For $CDMO To Consider: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174087779 Glta $CDMO Bulls, Watchers, & StockHOLDERS!

User Image Stock_Titan Posted - 1 week ago

$CDMO $CDMOP Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q https://www.stocktitan.net/news/CDMO/avid-bioservices-announces-receipt-of-deficiency-notice-from-nasdaq-74vaybghat50.html

User Image ForUS2Retire Posted - 1 week ago

Can $CDMO Touch $7 Before Close? Glta Bulls, Watchers, & StockHOLDERS!

User Image StockInvest_us Posted - 1 week ago

Signal alert: $CDMO - Oversold Trend Short (Undervalued) https://stockinvest.us/l/Q0b3IeYPnd

User Image ForUS2Retire Posted - 2 weeks ago

$CDMO Has Completed Refinancing Of Senior Notes And Has Also Reestablished Credit Line. Glta Bulls, Watchers, & StockHOLDERS! Link: https://ir.avidbio.com/sec-filings/sec-filing/8-k/0001683168-24-001462

User Image _www_larval_com_ Posted - 2 weeks ago

$CDMO has reversed 3% higher to -1% (~1Mv) a few minutes ago, 03/15 options, follow for more volatility.

User Image tepperoni Posted - 2 weeks ago

$CDMO lol fucking $1.4mil cost us 30% drop in share price. If cfo is not fired from this fuckup I’m out.

User Image DonCorleone77 Posted - 2 weeks ago

$CDMO Avid Bioservices to delay 10-Q filing, must restate Q3 financials The company stated: "As previously reported in a Current Report on Form 8-K, filed by Avid Bioservices, Inc. with the Securities and Exchange Commission on March 6, 2024, on February 29, 2024, the Company received an acceleration notice from a holder of its 1.250% Exchangeable Senior Notes due 2026. The Acceleration Notice stipulated, among other things, that (i) the Company did not remove the restrictive legend on the 2026 Notes by March 17, 2022 as required under the indenture governing the 2026 Notes , (ii) due to such failure, additional interest has accrued thereafter at a rate of 0.50% per annum, (iii) such Additional Interest had not been paid by the Company as of the date of the Acceleration Notice, which constitutes an event of default under the 2026 Notes Indenture, and (iv) such holder is the beneficial owner of at least 25% in aggregate principal amount of the outstanding 2026 Notes....

User Image GerardGielen97 Posted - 2 weeks ago

$CDMO greeeeen

User Image zamun Posted - 2 weeks ago

$CDMO nice dip buy at 6.06. How high can this go?

User Image ForUS2Retire Posted - 2 weeks ago

Didn’t The Contract With Oncologie Include A Clause… That If Oncologie Didn’t Do Certain Things That Bavi, BetaBodies, Etc., Would Revert Back To Avid? I Thought So, But Can’t Swear It Did. If Oncologie/OncXerna Is Truly Out Of Business, Where Does That Leave Those Contractually Linked Assets? Glta $CDMO Bulls, Watchers, & StockHOLDERS!

User Image KahlVados Posted - 2 weeks ago

$CDMO This is not something you recover from

User Image GerardGielen97 Posted - 2 weeks ago

$CDMO hup tik boem

User Image tepperoni Posted - 2 weeks ago

$CDMO Just think how much money and time it would cost to build a 20,000L plant nowadays, given the current inflation. The answer is quite straightforward. Oh but we should fucking fire that cfo. What a fucking joke he will never find another job lol

User Image Scooter0732 Posted - 2 weeks ago

$CDMO called this one wrong yesterday I guess I don’t see the opp until next qtr or the qtr after that cash is tight and now tighter, sales will take time to scale no major fda approvals yet except one, LoC is shot from default (May come back into compliance). I’ll wait and watch.

User Image ForUS2Retire Posted - 2 weeks ago

Will $CDMO Be Forced Into A Manipulated Buyout?... They Scrambled & Replaced The SeniorNotes At Higher Interest Rate, Which Could Strangle Profitability For Quite A While. BUT, They Still Need To Replace Their Revolving Credit Line That Also Got Canceled. They Have Been So Busy Building Their Expanded Infrastructure, But Can't Seem To Fill Their Capacity. By The Way, That $400 Million Capacity Is Still Only From A Single Daytime Workshift. Imagine If They Put On On A Second Or Third Shift???!!! Smoke & Mirrors. Someone Knew/Knows Something. I Would Not Be Surprised If That 25% Senior Note Holder That Caused The Recent Fiasco, May Actually Be Or Represent A Potential Buying Pharmaceutical Company. Glta Bulls, Watchers, & StockHOLDERS! Btw, PPS Heading up, Up, UP,... Again ;-) Either Avid Recovers Or The Buyer Forces A Lower Buyout, Which Will Be At Higher Than Current PPS!!!

User Image free_stock_alerts Posted - 2 weeks ago

$CDMO long over 6.50

User Image Fullratio Posted - 2 weeks ago

$CDMO price to book (P/B) is 81% less than its 5-year quarterly average of 10.8 and 52% less than its last 4 quarters average of 4.4: https://fullratio.com/stocks/nasdaq-cdmo/avid-bioservices

User Image kingofmaryland21 Posted - 2 weeks ago

$CDMO $CDMO I personally think the CFO and his entire finance team must get fired… but Avid will come out of this fine… give it another few months…we will bounce back up… biotech large investments are back

User Image valueforme Posted - 2 weeks ago

$CDMO After more thinking I sold as well, as the outcome of this balance sheet hole might be bigger than I initially estimated.

User Image Scooter0732 Posted - 2 weeks ago

$CDMO I’m going to stay out of this boondoggle for now. No catalysts until next Q and the mess up will cost them an additional 13mm in interest expenses per qtr plus closing costs at a time when cash is tight. It may bounce soft but don’t see a big rebound for a while. Glta

User Image valueforme Posted - 2 weeks ago

$CDMO Good summary of Senior Notes f*ckup https://www.ft.com/content/142097ae-9bb1-4c8b-ade5-4c3d2dfc2213

User Image valueforme Posted - 2 weeks ago

$CDMO Lol. The dude should be fired within next weeks.

User Image kingofmaryland21 Posted - 3 weeks ago

$CDMO obviously an overreaction - their debt convertible offering was at $9.80 something… this will bounce back up hard

User Image palm3 Posted - 3 weeks ago

$CDMO easy short

User Image free_stock_alerts Posted - 3 weeks ago

$CDMO we need to hold 6.25 bulls

User Image Jamesiam Posted - 3 weeks ago

$CDMO do they have enough cash to survive burning a lot of cash

User Image Plasma_star_9 Posted - 3 weeks ago

$CDMO 34% dip for a biopharma that actually has income and with an average price target $16 ? No brainer. Bought at $6.01 (and could have done better if I hadn't farted around). What ya waitin for--an invitation?

User Image valueforme Posted - 3 weeks ago

$CDMO This is the reason for this turmoil. They will figure this out, but their finance folks screwed things up.

User Image zamun Posted - 3 weeks ago

$CDMO Dip buy

Analyst Ratings
Stephens & Co. Overweight Mar 11, 24
RBC Capital Outperform Mar 7, 24
RBC Capital Outperform Dec 8, 23
Craig-Hallum Buy Dec 8, 23
Keybanc Overweight Dec 8, 23
William Blair Market Perform Sep 28, 23
RBC Capital Outperform Sep 8, 23
RBC Capital Outperform Jun 22, 23
Stephens & Co. Overweight Jun 22, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Kwietniak Matthew R. Chief Commercial Off.. Chief Commercial Officer Jan 11 Sell 6.77 274 1,855 19,829 01/12/24
Ziebell Mark R V. P., General Couns.. V. P., General Counsel Jan 09 Sell 6.17 1,346 8,305 63,269 01/11/24
Richieri Richard A. Chief Operations Off.. Chief Operations Officer Jan 09 Sell 6.17 1,171 7,225 5,208 01/11/24
Kwietniak Matthew R. Chief Commercial Off.. Chief Commercial Officer Jan 09 Sell 6.17 1,060 6,540 19,434 01/11/24
Hart Daniel R Chief Financial Offi.. Chief Financial Officer Jan 09 Sell 6.17 2,408 14,857 79,305 01/11/24
Hancock Richard B Director Director Dec 13 Buy 5.2067 38,803 202,036 117,563 01/10/24
Hancock Richard B Director Director Dec 14 Buy 5.86 23,000 134,780 78,760 12/18/23
Kwietniak Matthew R. Chief Commercial Off.. Chief Commercial Officer Oct 11 Sell 9.19 255 2,343 17,961 10/13/23
Ziebell Mark R V. P., General Couns.. V. P., General Counsel Oct 09 Sell 9.2 1,141 10,497 60,515 10/11/23
Richieri Richard A. Chief Operations Off.. Chief Operations Officer Oct 09 Sell 9.2 1,006 9,255 4,177 10/11/23
Kwietniak Matthew R. Chief Commercial Off.. Chief Commercial Officer Oct 09 Sell 9.2 970 8,924 17,546 10/11/23
Hart Daniel R Chief Financial Offi.. Chief Financial Officer Oct 09 Sell 9.2 2,040 18,768 75,081 10/11/23
Carleone Joseph Director Director Sep 21 Buy 9.5348 20,000 190,696 93,956 09/22/23
Green Nicholas Stewart President & CEO President & CEO Jul 30 Sell 12.99 19,519 253,552 145,844 08/01/23
Richieri Richard A. Chief Operations Off.. Chief Operations Officer Jul 13 Sell 13.40 2,734 36,636 4,035 07/14/23
Kwietniak Matthew R. Chief Commercial Off.. Chief Commercial Officer Jul 11 Sell 13.61 252 3,430 15,984 07/13/23
Ziebell Mark R V. P., General Couns.. V. P., General Counsel Jul 10 Sell 13.86 5,015 69,508 58,449 07/12/23
Richieri Richard A. Chief Operations Off.. Chief Operations Officer Jul 10 Sell 13.86 1,542 21,372 6,769 07/12/23
Hart Daniel R Chief Financial Offi.. Chief Financial Officer Jul 10 Sell 13.86 3,763 52,155 71,380 07/12/23
Ziebell Mark R V. P., General Couns.. V. P., General Counsel Jul 09 Sell 13.77 687 9,460 49,173 07/11/23
Richieri Richard A. Chief Operations Off.. Chief Operations Officer Jul 09 Sell 13.77 564 7,766 6,602 07/11/23
Kwietniak Matthew R. Chief Commercial Off.. Chief Commercial Officer Jul 09 Sell 13.77 477 6,568 15,567 07/11/23
Hart Daniel R Chief Financial Offi.. Chief Financial Officer Jul 09 Sell 13.77 1,269 17,474 64,420 07/11/23
Green Nicholas Stewart President & CEO President & CEO Jul 09 Sell 13.77 7,530 103,688 127,863 07/11/23
Ziebell Mark R V. P., General Couns.. V. P., General Counsel Jun 28 Sell 13.1 3,657 47,907 46,975 06/30/23
Richieri Richard A. Chief Operations Off.. Chief Operations Officer Jun 28 Sell 12.7 2,758 35,027 17,163 06/30/23
Kwietniak Matthew R. Chief Commerical Off.. Chief Commerical Officer Jun 28 Sell 12.7 3,947 50,127 14,067 06/30/23
Hart Daniel R Chief Financial Offi.. Chief Financial Officer Jun 28 Sell 12.7 6,884 87,427 61,141 06/30/23
Green Nicholas Stewart President & CEO President & CEO Jun 28 Sell 12.7 40,856 518,871 120,067 06/30/23
Hancock Richard B Director Director Jun 06 Sell 16.18 5,000 80,900 39,134 06/08/23
Hancock Richard B Director Director Jun 06 Option 4.53 12 54 39,146 06/08/23
Ziebell Mark R V. P., General Couns.. V. P., General Counsel May 01 Sell 17.91 25,000 447,750 40,119 05/02/23
Ziebell Mark R V. P., General Couns.. V. P., General Counsel May 01 Option 9.87 25,000 246,750 65,119 05/02/23
Hancock Richard B Director Director May 01 Sell 17.92 5,000 89,600 39,134 05/02/23
Hancock Richard B Director Director May 01 Option 4.67 5,000 23,350 44,134 05/02/23
Green Nicholas Stewart President & CEO President & CEO Apr 13 Sell 20.9165 7,000 146,416 83,531 04/14/23
SARGEN GREGORY Director Director Apr 11 Sell 20.2423 7,011 141,919 04/12/23
Ziebell Mark R V. P., General Couns.. V. P., General Counsel Apr 09 Sell 19.8 736 14,573 40,119 04/11/23
Hart Daniel R Chief Financial Offi.. Chief Financial Officer Apr 09 Sell 19.8 1,280 25,344 48,549 04/11/23
Green Nicholas Stewart President & CEO President & CEO Apr 09 Sell 19.8 7,598 150,440 90,531 04/11/23
Hart Daniel R Chief Financial Offi.. Chief Financial Officer Apr 05 Sell 19 1,250 23,750 46,207 04/07/23
Hart Daniel R Chief Financial Offi.. Chief Financial Officer Apr 05 Option 5.66 500 2,830 46,707 04/07/23
Hart Daniel R Chief Financial Offi.. Chief Financial Officer Mar 14 Sell 19 5,000 95,000 46,957 03/16/23
Hart Daniel R Chief Financial Offi.. Chief Financial Officer Mar 14 Option 5.66 2,000 11,320 48,957 03/16/23
Hancock Richard B Director Director Mar 01 Sell 16.59 5,000 82,950 39,134 03/03/23
Hancock Richard B Director Director Mar 01 Option 4.67 5,000 23,350 44,134 03/03/23
Hancock Richard B Director Director Feb 01 Sell 16.02 5,000 80,100 39,134 02/03/23
Hancock Richard B Director Director Feb 01 Option 4.67 5,000 23,350 44,134 02/03/23
Alegria Esther M. Director Director Jan 13 Sell 16.3233 5,321 86,856 01/17/23
Hancock Richard B Director Director Jan 12 Sell 16 5,000 80,000 39,134 01/13/23